Anzupgo (delgocitinib)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- delgocitinib
- Company
- LEO Pharma A/S
- Status
- Authorised
- Therapeutic area
- Dermatitis; Eczema
- CHMP opinion
- Thu 25 Jul 2024
- EU approval
- Thu 19 Sep 2024
- Designations
- Additional monitoring
- Application
- EMEA/H/C/006109
- ATC
- D11AH11
- Official record
- www.ema.europa.eu
Indication
Anzupgo is indicated for the treatment of moderate to severe chronic hand eczema (CHE) in adults and adolescents 12 years and older for whom topical corticosteroids are inadequate or inappropriate.
Regulatory milestones
No milestones recorded in the last year.
Follow Anzupgo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.